US FDA approves Regeneron's rare bone disorder drug
19/08/2026 19:02
US FDA approves Regeneron's rare bone disorder drug Aug 19 - The U.S. Food and Drug Administration on Wednesday approved Regeneron's REGN.O experimental treatment for a rare genetic disorder after the drug significantly reduced abnormal bone formation in certain soft tissues.
(Reporting by Bageshri Banerjee and Christy Santhosh in Bengaluru; Editing by Jonathan Ananda and Sahal Muhammed)
Recent news on Regeneron Pharmaceuticals
See all newsEyePoint to halve workforce after experimental drug fails second late-stage trial (updated)
EyePoint to cut workforce by half after experimental drug fails second late-stage trial
Brief: Sanofi, pCPA Sign Letter Of Intent For Dupixent® Across Four Indications In Dermatology, Respiratory Care
Brief: Regeneron Pharmaceuticals Says Pasatru Shows Sustained Efficacy & Consistent Safety Profile From Weeks 56 To 84
Brief: Regeneron Pharmaceuticals - Sanofi Enter Sixth Amendment To License And Collaboration Agreement